High monocytic MDSC signature predicts multi-drug resistance and cancer relapse in non-Hodgkin lymphoma patients treated with R-CHOP.
Dhar S, Chakravarti M, Ganguly N, Saha A, Dasgupta S, Bera S, Sarkar A, Roy K, Das J, Bhuniya A, Ghosh S, Sarkar M, Hajra S, Banerjee S, Pal C, Saha B, Mukherjee KK, Baral R, Bose A.
Dhar S, et al. Among authors: ganguly n.
Front Immunol. 2024 Jan 18;14:1303959. doi: 10.3389/fimmu.2023.1303959. eCollection 2023.
Front Immunol. 2024.
PMID: 38304256
Free PMC article.